Gossamer Bio Inc. (GOSS) Misses Q1 EPS by 7c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Needham Starts NeoVolta (NEOV) at Buy
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
Gossamer Bio Announces First Quarter 2020 Financial Results and Provides Corporate Update
May 12, 2020 4:01 PM EDT- GB001 interim analysis of LEDA trial in moderate-to-severe eosinophilic asthma completed -
- GB001 intellectual property estate strengthened with issuance of new patent by USPTO covering lysine salt drug substance forms -
- GB004 completed successful Phase 1b in ulcerative colitis; Phase 2 trial planned to commence in 2020 -
- GB004 license agreement with Aerpio amended to provide financial, milestone and royalty benefit to Gossamer -
- Chief Medical Officer Jakob Dupont, M.D. to depart Gossamer; will... More
